What Indications Can, And Will, mRNA Therapeutics Address?

During our Bioprocess Online Live event mRNA Update: Beyond Prophylactic Vaccines, we asked an audience of several hundred biopharma professionals what indications they’re addressing in mRNA therapeutic development. Here, Combined Therapeutics CSO Thomas Van Cott, Ph.D. and Omega Therapeutics Executive Director, Process Development and Analytical Sciences Jeff Atkinson, Ph.D. anticipate, and then address, their responses and offer some final thoughts on unfolding mRNA regulatory frameworks.

View the full presentation here.